The top analyst upgrades, downgrades and other research calls from Monday include Adobe, Apple, Bristol-Myers, Citigroup, Ford, Groupon, Phillips 66 and United Rentals.
U.S. pharmaceutical and biotech stocks may have considerable upside if Credit Suisse's views come to pass. But this part of the market has not come without controversy in the past year and…
The top analyst upgrades, downgrades and other research calls from Tuesday include Cheniere Energy, Consolidated Edison, Foot Locker, Shopify, Tesla, Veeco Instruments and Zoetis.
The top analyst upgrades, downgrades and initiations seen on Friday include Aerojet Rocketdyne, Alcoa, Amazon.com, ArcelorMittal, Corning, Intel, Vale and Advanced Micro Devices.
While worries about interest rates increases remain, it looks as though growth stocks still are the best avenue heading into the final two months of the year.
Is it possible that analysts are now behind the curve on Alkermes? Or worse, are they chasing their expectations too high?
Jon C. Ogg Alkermes' positive Phase 3 results for its novel antidepressant is serving as a rising tide — a storm surge even — for many biotech companies in the depression space.
While these were not the four biggest absolute losers of the week, they all issued news or had news that took place and pushed the stocks down.
Alkermes absolutely tanked early Thursday morning on less than favorable preliminary top-line results from the first two of three Phase 3 efficacy studies for ALKS 5461.
Chris Lange A report on Wednesday from Janney Capital Markets has targeted several iotech bcompanies it believes are now grossly oversold.
In a recent research report, Jefferies highlighted three top biotech companies that are very tempting buys now.
Tuesday's top analyst upgrades, downgrades and initiations include American Airlines, CyberArk Software, Delta Air Lines, First Solar and VMware.
24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of August and added some color.
24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of July and added some color.
Thursday's top analyst upgrades, downgrades and initiations include Alibaba, Mobileye, NetApp, Nike, Salesforce.com and Stratasys.
